2012
DOI: 10.1016/j.jjcc.2012.09.002
|View full text |Cite
|
Sign up to set email alerts
|

Short-term effects of low-dose tolvaptan on hemodynamic parameters in patients with chronic heart failure

Abstract: Short-term treatment with low-dose tolvaptan improved hemodynamic parameters and correlated with significant fluid removal in patients with chronic HF.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

1
41
2

Year Published

2013
2013
2019
2019

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 53 publications
(44 citation statements)
references
References 25 publications
1
41
2
Order By: Relevance
“…Our calculation, therefore, might not be accurate in terms of absolute values, although the trend of sodium excretion should still be valid. 5. We did not demonstrate direct involvement of ENaC or data on aldosterone concentration in the present study, although several previous reports demonstrated a signifi cant relationship between TLV and ENaC in sodium excretion in urine.…”
Section: Discussioncontrasting
confidence: 90%
See 1 more Smart Citation
“…Our calculation, therefore, might not be accurate in terms of absolute values, although the trend of sodium excretion should still be valid. 5. We did not demonstrate direct involvement of ENaC or data on aldosterone concentration in the present study, although several previous reports demonstrated a signifi cant relationship between TLV and ENaC in sodium excretion in urine.…”
Section: Discussioncontrasting
confidence: 90%
“…[3][4][5][6][7] We also reported the effi cacy and safety of TLV in (1) amelioration of congestion even in stage D HF patients and (2) improvement of renal function by converting ongoing diuretics to TLV. 8,9) With respect to serum sodium concentration (S-Na), various studies in Europe and the United States have demonstrated the effi cacy of TLV to improve hyponatremia with little chance of hypernatremia, ie, S-Na > 145 mEq/L (eg, 1.7% of hypernatremia in the EVEREST study and 0% in the QUEST study).…”
mentioning
confidence: 83%
“…4 One explanation may be that only excretion of free water, and not sodium, is enhanced; particularly in patients with hyponatremia and/or decreased serum osmolality, achieving fluid shift from the interstitial to the intravascular space is difficult. 5,6 The results of long-term treatment with vaptan-class drugs have already been reported in a study using satavaptan, which found no marked improvement in vital prognosis. 7 Those results suggest that blockage of V2 receptors may not lead to improvement of diminished systemic vascular resistance -which is the cause of hyponatremia -and that excessive diuresis may exacerbate the underfilling that underlies cirrhosis.…”
mentioning
confidence: 98%
“…[10][11][12][13][14][15][16][17] TLV has a specific feature of excreting only water without increasing electrolyte excretion because it functions as an antagonist to the vasopressin V2 receptor in renal collecting tubules. 18) In addition, it has been shown that TLV treatment resulted in favorable but modest changes in filling pressures (ie, pulmonary capillary wedge pressure, right atrial pressure, and pulmonary artery pressure) associated with a significant increase in urine output.…”
mentioning
confidence: 99%